BiotechTube

Comparator: pregabalin + Comparator: Placebo (unspecified)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuralgia, Postherpetic

Conditions

Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy, Idiopathic Distal Sensory Polyneuropathy

Trial Timeline

Dec 1, 2007 → Sep 1, 2008

NCT ID
NCT00570310

About Comparator: pregabalin + Comparator: Placebo (unspecified)

Comparator: pregabalin + Comparator: Placebo (unspecified) is a phase 1 stage product being developed by Merck for Neuralgia, Postherpetic. The current trial status is completed. This product is registered under clinical trial identifier NCT00570310. Target conditions include Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy.

What happened to similar drugs?

8 of 18 similar drugs in Neuralgia, Postherpetic were approved

Approved (8) Terminated (3) Active (8)
✅QUTENZAAstellas PharmaApproved
✅GalcanezumabEli LillyApproved
🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
✅Etoricoxib + PlaceboMerckApproved
✅pregabalinPfizerApproved
✅Lyrica (pregabalin) + PlaceboPfizerApproved
🔄placebo + pregabalinPfizerPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00570310Phase 1Completed

Competing Products

20 competing products in Neuralgia, Postherpetic

See all competitors
ProductCompanyStageHype Score
Placebo + DS-5565Daiichi SankyoPre-clinical
26
QUTENZAAstellas PharmaApproved
43
ASP8477 + PlaceboAstellas PharmaPhase 2
35
E2007 (perampanel) + PlaceboEisaiPhase 2
35
E2007EisaiPhase 2/3
38
KHK6188 + PlaceboKyowa KirinPhase 2
35
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
GalcanezumabEli LillyApproved
43
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
36
ABT-894 + ABT-894 + ABT-894 + placebo + DuloxetineAbbViePhase 2
35
MK-8291 + PlaceboMerckPhase 1
29
Etoricoxib + PlaceboMerckApproved
39
Cetuximab + PlaceboMerckPhase 2
35
ADL5747 + Placebo + PregabalinMerckPhase 2
27
MK0759MerckPhase 2
27
MK0686MerckPhase 2
27
EMA401 + PlaceboNovartisPhase 2
27
pregabalinPfizerApproved
43
Lyrica (pregabalin) + PlaceboPfizerApproved
43
2-weeks placebo then gabapentin + 1-week placebo then gabapentinPfizerPre-clinical
26